Skip to main content Skip to main navigation menu Skip to site footer
International Journal of Nutrology
Review
DOI: 10.54448/ijn23211
Submitted: 18-04-2023
Published: 19-04-2023

Major evidence of the GLP-1 analog (liraglutide) in the treatment of obesity: a systematic review

Tratte Clinic (Clínica Tratte), Rua Urbano Santos, 155 - Centro, Imperatriz - MA, 65900-410; Complement: Ed. Aracati - Sl 403
Obesity Liraglutide GLP-1 analogs Anti-obesity agents Weight loss

Abstract

Introduction: Obesity is a chronic disease that affects a significant portion of the population. In Brazil, in the surveillance survey of risk and protective factors for diseases, more than half of the Brazilian population, 55.7% are overweight. Objective: A systematic review of the literature was carried out with the primary objective of verifying the effectiveness of weight loss of liraglutide in obesity, the secondary objective is the evaluation and clinical benefits secondary to the medication. Methods: The systematic review rules of the PRISMA Platform were followed. The research was carried out from September to October 2022 in Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results: A total of 84 articles were found, 52 articles were evaluated and 20 were included in this systematic review. Considering the Cochrane tool for risk of bias, the overall assessment resulted in 8 studies with a high risk of bias and 19 studies that did not meet GRADE. Most studies showed homogeneity in their results, with X2 =96.9% >50%. In this context of a serious disease with a high prevalence in the population, a literature review was carried out to verify the effectiveness of weight loss of liraglutide 3.0mg in obesity. A total of 781 works were found, of which all titles and abstracts were individually evaluated and sixteen related to the clinical question and PICOS were selected. Primary studies show the superiority of liraglutide over placebo and orlistat in weight loss and improvements in clinical outcomes. Conclusion: Liraglutide 3.0mg proved to be a safe and effective option in the treatment of obesity.

Metrics

Metrics Loading ...

References

  1. Iqbal J, Wu HX, Hu N, Zhou YH, Li L, Xiao F, Wang T, Jiang HL, Xu SN, Huang BL, Zhou HD. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev. 2022 Jun;23(6):e13435. doi: 10.1111/obr.13435.
  2. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022 Mar;57:101351. doi: 10.1016/j.molmet.2021.101351. Epub 2021 Oct 6.
  3. Pesquisa Nacional de Saúde 2019. Instituto Brasileiro de Geografia e Estatística. Rio de Janeiro; 2020.
  4. Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020; 382(22):2117-2128. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32233338/.
  5. Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica Diretrizes brasileiras de obesidade. ABESO – Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica. 4 ed. São Paulo, 2016.
  6. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. The New England journal of medicine. 2015;373(1): 11–22. Disponível em: https://pubmed.ncbi.nlm.nih.gov/26132939/.
  7. Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017; 389(10077):1399-1409. Disponível em: ttps://pubmed.ncbi.nlm.nih.gov/28237263/.
  8. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015; 314(7):687-699.
  9. Wadden TA, Walsh OA, Berkowitz RI, Chao AM, Alamuddin N, Gruber K, et al. Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial. Obesity (Silver Spring). 2019; 27(1):75-86. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800068/.
  10. Wharton S, Liu A, Pakseresht A, Nortoft E, Haase CL, Mancini J, et al. Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada. Obesity (Silver Spring).2019;27(6):917924. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31062937/.
  11. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, doubleblind,placebo-controlledstudy. Lancet. 2009;374(9701):1606- 16. Disponível em: https://pubmed.ncbi.nlm.nih.gov/19853906/.
  12. Gorgojo-Martínez JJ, Basagoiti-Carreño B, Sanz-Velasco A, Serrano-Moreno C, Almodóvar-Ruiz F. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study. Int J Clin Pract. 2019;73(11):e13399. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31397946/.
  13. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-dietinduced weight loss: the SCALE Maintenance randomized study. International journal of obesity. 2013;37(11):1443–1451. Disponível em: https://pubmed.ncbi.nlm.nih.gov/23812094/.
  14. Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposureresponse analyses of liraglutide 3.0mg for weight management. Diabetes Obes Metab. 2016;18(5):491-499. Disponível em: https://pubmed.ncbi.nlm.nih.gov/26833744/.
  15. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3-14. Disponível em: https://pubmed.ncbi.nlm.nih.gov/28392927/.
  16. Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and metaanalysis of randomized controlled trials of anti-obesity drugs.(Em processo de publicação) Expert Rev Clin Pharmacol. 2020; 13(1):53-64. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31770497/.
  17. Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319. Disponível em: https://pubmed.ncbi.nlm.nih.gov/27005405/.
  18. Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity (Silver Spring). 2020;28(3):529-536. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32090517/.
  19. O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose- ranging, phase 2 trial. Lancet. 2018;392(10148):637-649. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30122305/.
  20. Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019; 394 (10192):39-50. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31186120/.

How to Cite

Fernandes, F. B. (2023). Major evidence of the GLP-1 analog (liraglutide) in the treatment of obesity: a systematic review. International Journal of Nutrology, 16(2). https://doi.org/10.54448/ijn23211